ICOcap is our new dry powder inhaler: Capsule-based and easy to use. Find out more!
Home - Integrated solutions for pharma & healthcare - Stevanato Group > Offering - Stevanato Group > Drug Delivery Systems - Stevanato Group > Proprietary and licensed devices - Stevanato Group > Dry powder inhaler ICOcap - Stevanato Group
ICOcap® is a capsule based Dry Powder Inhaler with superior handling features. Closely collaborating with the inhaling experts of Iconovo, optional formulation development support completes the offering.
ICOcap® - Inhaler
ICOcap® is a capsule based Dry Powder Inhaler with superior handling features. Closely collaborating with the inhaling experts of Iconovo, optional formulation development support completes the offering.
User friendly inhaler for Drug Delivery to the lung
ICOcap® is Stevanato's portfolio inhaler offered to the market. It is a device solution for pharmaceutical companies who are focusing on therapeutical disease treatments as asthma and COPD.
ICOcap Airflow Animation (HQ)
Watch Video
Features
Reliability due to a robust design
CE marked device
FDA: Type III Drug Master File
For pre-filled drug formulations in size 3 capsules
Affordable price
Low flow resistance
Only 6 injection molded parts, needles and springs
Features
Reliability due to a robust design
CE marked device
FDA: Type III Drug Master File
For pre-filled drug formulations in size 3 capsules
Affordable price
Low flow resistance
Only 6 injection molded parts, needles and springs
Therapeutic Areas
Asthma
COPD
Further indications as Cystic Fibrosis, Pulmonary Hypertension, Idiopathic pulmonary fibrosis, etc.
Therapeutic Areas
Asthma
COPD
Further indications as Cystic Fibrosis, Pulmonary Hypertension, Idiopathic pulmonary fibrosis, etc.
Benefits
CE-marked
FDA: Type III Drug Master File
Patented One-Piece-Design: Cap remains attached when open
Support in formulation development by our partner Iconovo
Optimized size, easy handling
Benefits
CE-marked
FDA: Type III Drug Master File
Patented One-Piece-Design: Cap remains attached when open
Support in formulation development by our partner Iconovo
EN
IT
DE
JP
CN
ES
